Fusion Antibodies stock price, funding rounds, valuation and financials

Fusion Antibodies has raised $2.50 m in total funding. Fusion Antibodies annual revenue was £2.18 m in FY 2019

£2.2 M

Fusion Antibodies Revenue FY, 2019
Fusion Antibodies Net income (FY, 2019)-1.3 M
Fusion Antibodies EBIT (FY, 2019)-1.5 M
Fusion Antibodies Cash, 31-Mar-20192 M

Fusion Antibodies Funding

Summary Metrics

Founding Date

2001

Fusion Antibodies total Funding

$2.5 m

Fusion Antibodies latest funding size

$2.50 m

Time since last funding

12 years ago

Fusion Antibodies investors

Fusion Antibodies's latest funding round in July 2007 was reported to be $2.5 m. In total, Fusion Antibodies has raised $2.5 m

Fusion Antibodies Income Statement

Annual

GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

609.3k455.9k461.1k436.9k492.3k435.2k405.0k723.0k1.5m1.9m2.7m2.2m

Revenue growth, %

79%

Cost of goods sold

802.9k255.2k248.6k196.3k298.7k361.7k324.2k365.3k618.1k952.5k1.2m

Gross profit

(193.6k)200.7k212.4k240.6k193.6k73.5k80.8k357.7k863.2k961.5k1.5m

Gross profit Margin, %

(32%)44%46%55%39%17%20%49%58%50%55%

Operating expense total

688.4k1.4m1.6m1.3m804.6k841.5k554.0k477.1k835.5k835.0k2.2m

Depreciation and amortization

431.2k

EBITDA

(818.3k)(1.1m)(1.3m)(944.2k)(493.7k)(707.6k)(444.7k)(101.1k)159.5k(640.9k)

EBITDA margin, %

(134%)(248%)(277%)(216%)(100%)(163%)(110%)(14%)8%(24%)

EBIT

(882.0k)(1.2m)(1.4m)(1.0m)(611.0k)(767.9k)(473.2k)(119.4k)27.7k126.5k(710.5k)(1.5m)

EBIT margin, %

(145%)(267%)(294%)(232%)(124%)(176%)(117%)(17%)2%7%(26%)(69%)

Interest expense

4.0k

Pre tax profit

(872.6k)(1.2m)(1.3m)(1.0m)(611.9k)(768.5k)(473.6k)(120.5k)2.3m125.9k(711.4k)(1.5m)

Income tax expense

56.7k55.9k18.2k55.1k78.0k16.3k4.9k6.9k(1.1m)(6.0k)11.4k235.5k

Net Income

(815.8k)(1.1m)(1.3m)(960.2k)(533.9k)(752.2k)(468.7k)(113.5k)1.2m120.0k(699.9k)(1.3m)

Fusion Antibodies Balance Sheet

Annual

GBPFY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

8.8k19.4k20.8k369.5k62.1k165.3k436.8k127.9k318.5k126.2k45.1k129.0k139.1k103.6k413.9k285.7k4.5m2.0m

Accounts Receivable

198.0k151.5k189.4k99.4k263.5k89.6k92.1k86.5k205.3k241.7k510.0k510.9k726.3k

Inventories

10.9k32.7k39.0k43.6k70.3k81.8k242.7k

Current Assets

23.2k110.7k198.9k645.4k384.0k645.3k783.7k508.5k565.5k563.8k287.6k248.3k269.2k309.0k691.6k930.0k5.5m3.3m

PP&E

107.9k90.4k95.8k86.7k110.3k409.9k333.4k312.0k253.8k141.1k82.7k55.4k44.7k36.4k1.2m107.3k546.7k1.6m

Total Assets

191.0k261.1k354.7k786.1k542.3k1.1m1.1m820.5k819.3k704.8k370.3k303.7k313.9k345.4k1.9m2.2m7.2m6.2m

Accounts Payable

159.1k158.0k334.1k179.7k187.6k262.5k224.3k258.8k181.7k98.4k245.6k281.3k461.8k

Short-term debt

66.5k

Current Liabilities

46.3k112.2k124.1k119.3k222.7k389.7k414.1k600.5k280.6k361.9k422.7k253.6k297.6k181.7k391.4k430.2k570.1k795.9k

Long-term debt

72.6k

Non-Current Liabilities

25.0k55.3k21.1k97.5k67.5k57.5k47.9k32.2k23.9k20.0k20.0k20.0k20.0k20.0k20.0k20.0k63.5k92.6k

Total Debt

30.2k82.4k79.6k8.6k139.2k

Total Liabilities

71.3k167.6k145.2k216.8k290.2k447.2k462.0k632.6k304.6k381.9k442.7k273.6k317.6k201.7k411.4k450.2k633.6k888.5k

Common Stock

203.5k203.5k210.1k135.8k135.8k195.8k236.3k266.0k354.2k389.0k466.5k523.6k531.6k547.6k547.7k547.7k883.6k883.6k

Retained Earnings

(6.4m)(6.6m)(6.6m)(5.3m)(5.0m)819.1k(401.9k)

Total Equity

119.7k93.6k209.5k569.4k252.0k608.1k655.1k187.9k514.7k322.9k(72.5k)30.1k(3.7k)143.8k1.5m1.7m6.6m5.4m

Debt to Equity Ratio

0 x0.1 x0.4 x0 x

Debt to Assets Ratio

0 x0.1 x0.1 x0 x

Financial Leverage

1.6 x2.8 x1.7 x1.4 x2.2 x1.7 x1.7 x4.4 x1.6 x2.2 x-5.1 x10.1 x-85.3 x2.4 x1.3 x1.3 x1.1 x1.2 x

Fusion Antibodies Cash Flow

Annual

GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2016FY, 2017FY, 2018

Net Income

(815.8k)(1.1m)(1.3m)(960.2k)(533.9k)(752.2k)(468.7k)(113.5k)1.2m120.0k(699.9k)

Cash From Operating Activities

346.6k(37.4k)77.2k

Cash From Financing Activities

(496.0)(615.0)4.6m

Net Change in Cash

310.3k(128.3k)4.2m

Income Taxes Paid

6.9k

Fusion Antibodies Ratios

GBPY, 2019

Revenue/Employee

76.3k

Financial Leverage

1.2 x